Munich, Germany

Petra Sichel

This inventor holds 2 USPTO granted patents. Top assignee: Hoechst Aktiengesellschaft. Active years: 1997-1998.


% Patents Active = 100.0

Average Co-Inventor Count = 4.2

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 1997-1998

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Petra Sichel: Innovator in Secondary-Metabolite Biosynthesis

Introduction

Petra Sichel is a prominent inventor based in Munich, Germany. She has made significant contributions to the field of biosynthesis, particularly focusing on secondary-metabolite biosynthesis genes from actinomycetes. Her work has implications for various applications in biotechnology and pharmaceuticals.

Latest Patents

Petra Sichel holds 2 patents related to her innovative research. Her latest patents include "Secondary-metabolite biosynthesis genes from actinomycetes" and "Method of isolating them, and their use." These inventions detail a method for isolating secondary-metabolite biosynthesis genes, specifically 6-deoxy-sugar biosynthesis genes, from actinomycetes using gene probes from Streptomyces griseus DSM40236. The patents also describe the use of these isolated genes in various applications.

Career Highlights

Throughout her career, Petra has been associated with Hoechst Aktiengesellschaft, where she has contributed to groundbreaking research in her field. Her work has not only advanced scientific understanding but has also paved the way for practical applications in biotechnology.

Collaborations

Petra Sichel has collaborated with notable colleagues, including Wolfgang Piepersberg and Michael Stockmann. These collaborations have enriched her research and expanded the impact of her inventions.

Conclusion

Petra Sichel's contributions to the field of secondary-metabolite biosynthesis highlight her role as an influential inventor. Her patents and collaborative efforts continue to shape advancements in biotechnology and related industries.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…